

=> b reg
 FILE 'REGISTRY' ENTERED AT 15:20:49 ON 18 OCT 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7
 DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> d que sta 16


L2 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
 L3 370 SEA FILE=REGISTRY SSS FUL L2
 L4 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE
 L6 9 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

100.0% PROCESSED 27 ITERATIONS
 SEARCH TIME: 00.00.01

9 ANSWERS


=> d que sta l17
 L2 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
 L3 370 SEA FILE=REGISTRY SSS FUL L2
 L15 STR



Page 1-A

HO- C C
55 @56 57

Page 2-A

VAR G1=33/44/45/36/40/46/48/51/56

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 57

STEREO ATTRIBUTES: NONE

L17 13 SEA FILE=REGISTRY SUB=L3 SSS FUL L15

100.0% PROCESSED 184 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.01

=> d bib abs hitstr l14 tot

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> b hcap

FILE 'HCAPLUS' ENTERED AT 15:21:37 ON 18 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2007 VOL 147 ISS 17

FILE LAST UPDATED: 17 Oct 2007 (20071017/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr l14 tot

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:162374 HCAPLUS

DN 146:492765

TI Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression

AU Wang, Zhong; Lecane, Philip S.; Thiemann, Patricia; Fan, Qing; Cortez, Cecilia; Ma, Xuan; Tonev, Danielle; Miles, Dale; Naumovski, Louie; Miller, Richard A.; Magda, Darren; Cho, Dong-Gyu; Sessler, Jonathan L.; Pike, Brian L.; Yeligar, Samantha M.; Karaman, Mazen W.; Hacia, Joseph G.

CS Pharmacoclytics, Inc., Sunnyvale, CA, USA

SO Molecular Cancer (2007), 6, No pp. given

CODEN: MCOACG; ISSN: 1476-4598

URL: <http://www.molecular-cancer.com/content/pdf/1476-4598-6-9.pdf>

PB BioMed Central Ltd.

DT Journal; (online computer file)

LA English

AB Background: Sapphyrin analogs and related porphyrin-like species have attracted attention as anticancer agents due to their selective localization in various cancers, including hematol. malignancies, relative to surrounding tissues. Sapphyrins are electron affinic compds. that generate high yields of singlet oxygen formation. Although initially explored in the context of photodynamic therapy, sapphyrins have intrinsic anticancer activity that is independent of their photosensitizing properties. However, the mechanisms for their anticancer activity have not been fully elucidated. Results: the authors have prepared a series of hydrophilic sapphyrins and evaluated their effect on proliferation, uptake, and cell death in adherent human lung (A549) and prostate (PC3) cancer cell lines and in an A549 xenograft tumor model. PCI-2050, the sapphyrin derivative with the highest in vitro growth inhibitory activity, significantly lowered 5-bromo-2'-deoxyuridine incorporation in S-phase A549 cells by 60% within eight hours and increased levels of reactive oxygen species within four hours. The growth inhibition pattern of PCI-2050 in the National Cancer Institute 60 cell line screen correlated most closely using the COMPARE algorithm with known transcriptional or translational inhibitors. Gene expression analyses conducted on A549 plateau phase cultures treated with PCI-2050 uncovered wide-spread decreases in mRNA levels, which especially affected short-lived transcripts. Intriguingly, PCI-2050 increased the levels of transcripts involved in RNA processing and trafficking, transcriptional regulation, and chromatin remodeling. The authors propose that these changes reflect the activation of cellular processes aimed at countering the observed wide-spread redns. in transcript levels. In the authors' A549 xenograft model, the two lead compds., PCI-2050 and PCI-2022, showed similar tumor distributions despite differences in plasma and kidney level profiles. This provides a possible explanation for the better tolerance of PCI-2022 relative to PCI-2050. Conclusion: Hydrophilic sapphyrins were found to display promise as novel agents that localize to tumors, generate oxidative stress, and inhibit gene expression.

IT 924905-80-6, PCI 2050 936576-25-9, PCI 2012

936576-26-0, PCI 2022 936576-27-1, PCI 2042


RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydrophilic sapphyrins were found to display promise as novel agents that localize to tumors, generate oxidative stress, and inhibit gene expression)


RN 924905-80-6 HCAPLUS

CN 5,8,11-Trioxa-2-azadodecanoic acid, 2-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-, 1,1'-[(4,13,14,23-tetraethyl-3,8,19,24-tetramethyl-25,26,27,28,29-pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosapenta-1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-propanediyl] ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




PAGE 1-C

CH₂ CH₂ - OMeO - CH₂ - CH₂ - OMe


RN 936576-25-9 HCAPLUS

CN Carbamic acid, N,N-bis(2-hydroxyethyl)-, C,C'-[(4,13,14,23-tetraethyl-3,8,19,24-tetramethyl-25,26,27,28,29-pentaazahehexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-propanediyl] ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 936576-26-0 HCAPLUS
 CN Carbamic acid, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-,
 C,C'-[(4,13,14,23-tetraethyl-3,8,19,24-tetramethyl-25,26,27,28,29-
 pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-
 1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-
 propanediyl] ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 936576-27-1 HCAPLUS
 CN D-Glucose, 2,2'-[(4,13,14,23-tetraethyl-3,8,19,24-tetramethyl-
 25,26,27,28,29-pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-
 1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)bis(3,1-
 propanediyl)oxycarbonylimino]]bis[2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OH

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1236185 HCAPLUS
DN 146:220114
TI Tumor localization and antitumor efficacy of novel sapphyrin compounds
AU Naumovski, Louie; Sirisawad, Mint; Lecane, Philip; Chen, Jun; Ramos, Jason; Wang, Zhong; Cortez, Cecilia; Magda, Darren; Thiemann, Patti; Boswell, Garry; Miles, Dale; Cho, Dong Gyu; Sessler, Jonathan L.; Miller, Richard
CS Pharmacyclics, Inc., Sunnyvale, CA, USA
SO Molecular Cancer Therapeutics (2006), 5(11), 2798-2805
CODEN: MCTOCF; ISSN: 1535-7163
PB American Association for Cancer Research
DT Journal
LA English
AB Sapphyrins are pentapyrrolic metal-free expanded porphyrins with potential medical use as anticancer agents. The novel sapphyrin derivative, PCI-2050, functionalized with 2-[2-(2-methoxyethoxy)ethoxy]ethoxy groups to enhance

solubility and a modified bipyrrrole moiety was more potent in inducing apoptosis than the previously described sapphyrin PCI-2000. Because some sapphyrins may localize to tumors, we took advantage of the intrinsic fluorescence of these compds. to develop a flow cytometry-based assay to track sapphyrin biodistribution in tumor-bearing mice. Ex vivo anal. of sapphyrin-injected animals revealed that PCI-2050 preferentially localized to tumor, whereas PCI-2000 distributed into normal tissues rather than tumor. PCI-2050 uptake in xenograft tumor cells and resultant tumor cell cytotoxicity was dose dependent. To investigate structure-activity relationships, we focused on PCI-2050 and three derivs. that differ by their alkyl substituents on the bipyrrrole moiety: PCI-2051, PCI-2052, and PCI-2053. Treatment of Ramos cells in culture or treatment of Ramos xenograft-bearing animals with each of the sapphyrins followed by ex vivo growth of tumor cells revealed the same pattern of cytotoxicity: PCI-2050 > PCI-2052 > PCI-2051 > PCI-2053. Thus, subtle changes in the alkyl substituents on the bipyrrrole moiety result in significant changes in antitumor activity. PCI-2050 displayed significant antitumor efficacy in both Ramos and RKO xenograft models without hematol., hepatic, or renal abnormalities as assessed by complete blood counts and serum chemistries. On the basis of these findings, it is concluded that the sapphyrin PCI-2050 warrants further evaluation as a potential anticancer agent due to its intrinsic proapoptotic activity and tumor localization ability.

IT 924905-80-6, PCI 2050 924905-81-7, PCI 2051

924905-82-8, PCI 2052 924905-83-9, PCI 2053


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tumor localization and antitumor efficacy of novel sapphyrin compds.)


RN 924905-80-6 HCAPLUS

CN 5,8,11-Trioxa-2-azadodecanoic acid, 2-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-, 1,1'-[(4,13,14,23-tetraethyl-3,8,19,24-tetramethyl-25,26,27,28,29-pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-propanediyl] ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C


$$\text{CH}_2\text{---CH}_2\text{---OMe}$$

$$\text{---O---CH}_2\text{---CH}_2\text{---OMe}$$


RN 924905-81-7 HCAPLUS

CN 5,8,11-Trioxa-2-azadodecanoic acid, 2-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-
 , 1,1'-[(3,4,13,14,23,24-hexaethyl-8,19-dimethyl-25,26,27,28,29-
 pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-
 1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-
 propanediyl] ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C


$$\text{---CH}_2\text{---CH}_2\text{---OMe}$$

$$\text{---O---CH}_2\text{---CH}_2\text{---OMe}$$


RN 924905-82-8 HCAPLUS

CN 5,8,11-Trioxa-2-azadodecanoic acid, 2-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-
 , 1,1'-[(13,14-diethyl-3,4,8,19,23,24-hexamethyl-25,26,27,28,29-
 pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-
 1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-
 propanediyl] ester (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 924905-83-9 HCAPLUS

CN 5,8,11-Trioxa-2-azadodecanoic acid, 2-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-
 , 1,1'-[(13,14-diethyl-8,19-dimethyl-25,26,27,28,29-
 pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-
 1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-
 propanediyl] ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C

---CH₂-CH₂-OMe—O-CH₂-CH₂-OMe

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:511839 HCAPLUS
DN 143:259655
TI Sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show in vivo antitumor activity
AU Naumovski, Louie; Ramos, Jason; Sirisawad, Mint; Chen, Jun; Thiemann, Patti; Lecane, Philip; Magda, Darren; Wang, Zhong; Cortez, Cecilia; Boswell, Garry; Cho, Dong Gyu; Sessler, Jonathan; Miller, Richard
CS Pharmacoclytics, Inc., Sunnyvale, CA, 94085, USA
SO Molecular Cancer Therapeutics (2005), 4(6), 968-976
CODEN: MCTOCF; ISSN: 1535-7163
PB American Association for Cancer Research
DT Journal
LA English
AB Sapphyrins are pentapyrrolic, metal-free, expanded porphyrins. In the present study, the activity of sapphyrins as anticancer agents in hematopoietic-derived tumor cells was explored. It was found that a dihydroxylated water-soluble sapphyrin derivative (PCI-2000) is a potent inducer of apoptosis in a wide variety of tumor cell lines including lymphoma (Ramos, DHL-4, and HF-1), leukemia (Jurkat and HL-60), and myeloma (8226/S, 1-310, C2E3, and 1-414). PCI-2000 triggers an apoptotic pathway in these tumor cells as shown by release of cytochrome c from mitochondria; activation of caspases 9, 8, and 3; cleavage of the caspase substrate poly(ADP-ribose) polymerase; and Annexin V binding. Apoptosis can be partially inhibited by overexpression of the antiapoptotic protein Bcl-2 or treatment with benzyloxycarbonyl-valine-alanine-aspartic acid-fluoromethylketone, a cell-permeable caspase inhibitor. Both PCI-2000 and PCI-2010, a tetrahydroxy bis-carbamate derivative of PCI-2000, result in increased levels of phosphorylated p38 mitogen-activated protein kinase. Inhibition of p38 mitogen-activated protein kinase

phosphorylation resulted in a synergistic increase of PCI-2000 cytotoxicity. PCI-2010 showed less toxicity in mice than PCI-2000 and was active in slowing the growth of Ramos and HL-60 tumor xenografts in nude mice. These results provide preclin. rationale for the further study of sapphyrins for potential use in the treatment of hematopoietic-derived tumors.


IT 777931-97-2, PCI 2010

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show antitumor activity)


RN 777931-97-2 HCAPLUS

CN Carbamic acid, bis(2-hydroxyethyl)-, (3,4,13,14,23,24-hexaethyl-8,19-dimethyl-25,26,27,28,29-pentaazahehexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-propanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:872660 HCAPLUS

DN 141:360663

TI Sapphyrins and their uses to treat neoplasm

IN Magda, Darren; Sessler, Jonathan L.; Wang, Zhong

PA Pharmacyclics, Inc., USA; Board of Regents, University of Texas System

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004089300	A2	20041021	2004WO-US10481	20040405
	WO2004089300	A3	20050811		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG

AU2004228050 A1 20041021 2004AU-0228050 20040405
 CA---2520452 A1 20041021 2004CA-2520452 20040405
 EP---1615552 A2 20060118 2004EP-0758893 20040405

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP2006522156 T 20060928 2006JP-0509717 20040405
 US2006241166 A1 20061026 2006US-0552696 20060713 <--

PRAI 2003US-460846P P 20030404
 2003US-520275P P 20031113
 2003US-527510P P 20031205
 2004WO-US10481 W 20040405

OS MARPAT 141:360663

AB The present invention relates to sapphyrins, their pharmaceutical composition, and their utility in treating neoplasm. For example, carbamate-linked tetrahydroxy-sapphyrin was prepared. Bishydroxypropyl-sapphyrin (100 mg, 0.145 mmol) and 186 mg (0.725 mmol) of N,N'-disuccinimidyl carbonate were placed in a Schlenk tube, and 187 mg (1.45 mmol) of diisopropylethylamine and 5 mL CH₂Cl₂ were added, and the reaction mixture was stirred at room temperature for 4 h. Diethanolamine (152 mg, 1.45 mmol) dissolved in 1 mL CH₂Cl₂ was added, and the resulting mixture was stirred for another hour. The reaction mixture was concentrated to give an oily residue, and purified to yield 75 mg (51%) of tetrahydroxy-carbamate-sapphyrin (as monoacetate). Also, the effects of various sapphyrins when added to Ramos cells in causing cell death were presented.

IT 777931-97-2P 777931-98-3P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sapphyrins for treatment of neoplasm)


RN 777931-97-2 HCAPLUS

CN Carbamic acid, bis(2-hydroxyethyl)-, (3,4,13,14,23,24-hexaethyl-8,19-dimethyl-25,26,27,28,29-pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-propanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 777931-98-3 HCAPLUS
 CN Carbamic acid, bis(2-hydroxyethyl)-, (3,4,13,14,23,24-hexaethyl-8,19-dimethyl-25,26,27,28,29-pentaazahehexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-diyl)di-3,1-propanediyl ester, monoacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 777931-97-2
 CMF C54 H75 N7 O8

PAGE 1-A




PAGE 1-B



CM 2


CRN 64-19-7
 CMF C2 H4 O2



=> d bib abs hitstr 120 tot

L20 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:314979 HCAPLUS
 DN 145:7911
 TI Synthesis and Diels-Alder reaction of a sapphyrin derivative
 AU Tome, Joao P. C.; Cho, Dong-Gyu; Sessler, Jonathan L.; Neves, Maria G. P. M. S.; Tome, Augusto C.; Silva, Artur M. S.; Cavaleiro, Jose A. S.
 CS Department of Chemistry and Biochemistry, The University of Texas at Austin, Austin, TX, 78712-0165, USA
 SO Tetrahedron Letters (2006), 47(18), 3131-3134
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier B.V.
 DT Journal
 LA English

OS CASREACT 145:7911
 AB Sapphyrins participate in Diels-Alder reactions with pentacene affording novel barrelene-fused sapphyrins. The new compds. were synthesized using traditional heating and microwave irradiation conditions. The expts. carried out under microwave irradiation proved cleaner, affording only the monoadduct and in higher yields.
 IT 888028-62-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and Diels-Alder reaction of a sapphyrin derivative)
 RN 888028-62-4 HCAPLUS
 CN 25,26,27,28,29-Pentaazahexacyclo[20.2.1.12,5.17,10.112,15.117,20]nonacosa-1,3,5,7(28),8,10,12,14,16,18,20(26),21,23-tridecaene-9,18-dipropanol, 13,14-diethyl-8,19-dimethyl-, diacetate (ester) (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:41:30 ON 18 OCT 2007)

FILE 'HCAPLUS' ENTERED AT 14:41:43 ON 18 OCT 2007
 ACT J696APP/A

L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US20060241166/PN

FILE 'REGISTRY' ENTERED AT 14:41:58 ON 18 OCT 2007
 ACT J696C1/A

L2 STR
 L3 370 SEA FILE=REGISTRY SSS FUL L2

FILE 'STNGUIDE' ENTERED AT 14:43:16 ON 18 OCT 2007

FILE 'REGISTRY' ENTERED AT 14:52:01 ON 18 OCT 2007

L4 STR L2
 L5 3 L4 SAM SUB=L3
 L6 9 L4 FULL SUB=L3
 SAV TEM L6 J696C2/A

FILE 'HCAPLUS' ENTERED AT 14:57:23 ON 18 OCT 2007

L7 TRA L1 1- RN : 7 TERMS

FILE 'REGISTRY' ENTERED AT 14:57:23 ON 18 OCT 2007

L8 7 SEA L7
 L9 2 L6 AND L8

FILE 'HCAPLUS' ENTERED AT 14:57:50 ON 18 OCT 2007

L10 4 L6
 L11 1 L10 AND L1
 E MAGDA D/AU
 L12 73 E3,E6-7
 L13 4 L10 AND L12
 L14 4 L11,L13

FILE 'STNGUIDE' ENTERED AT 14:59:51 ON 18 OCT 2007

FILE 'REGISTRY' ENTERED AT 15:03:18 ON 18 OCT 2007

L15 STR L4
 L16 3 L15 SAM SUB=L3
 L17 13 L15 FULL SUB=L3

SAV TEM J696U103/A L17
L18 4 L17 NOT L6
L19 1 C40H45N5O4 AND L18

FILE 'HCAPLUS' ENTERED AT 15:19:22 ON 18 OCT 2007
L20 1 L19

FILE 'HCAOLD' ENTERED AT 15:20:14 ON 18 OCT 2007
L21 0 L17

=>

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	23	"5543514"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/18 14:19
L2	30	magda.in. and "540".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/18 14:19
L3	13	magda.in. and "540".clas. and sapphyrin\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/18 14:25
L4	17	I2 not I3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/18 14:25